Key Points
- Director Geno Germano bought 20,000 shares on March 9 at an average price of $1.30 (total $26,000), doubling his stake to 40,000 shares valued at about $52,000, per an SEC filing.
- ENTX shares traded around $1.36 with a market cap of roughly $62.4M and a 1‑year range of $1.00–$3.22; analyst coverage is mixed but the MarketBeat consensus is a Hold with a $10.00 consensus price target.
- Several hedge funds (including Seven Fleet, Superstring, Schonfeld, Jane Street and Renaissance) adjusted positions in Q4, and institutional investors now own about 14.11% of the company.
Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) Director Geno Germano bought 20,000 shares of the stock in a transaction on Monday, March 9th. The shares were acquired at an average cost of $1.30 per share, with a total value of $26,000.00. Following the acquisition, the director directly owned 40,000 shares in the company, valued at approximately $52,000. This trade represents a 100.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Entera Bio Price Performance
Shares of ENTX stock traded down $0.03 during trading hours on Thursday, reaching $1.36. The company had a trading volume of 22,567 shares, compared to its average volume of 211,824. Entera Bio Ltd. has a 1-year low of $1.00 and a 1-year high of $3.22. The firm has a market cap of $62.37 million, a price-to-earnings ratio of -5.44 and a beta of 1.83. The company has a 50 day moving average of $1.48 and a 200 day moving average of $1.96.
Institutional Trading of Entera Bio
Several hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP bought a new position in Entera Bio during the fourth quarter worth about $263,000. Superstring Capital Management LP acquired a new stake in shares of Entera Bio during the fourth quarter worth about $33,000. Schonfeld Strategic Advisors LLC raised its position in shares of Entera Bio by 5.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company's stock worth $1,157,000 after purchasing an additional 29,629 shares during the period. Jane Street Group LLC lifted its holdings in shares of Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock valued at $144,000 after purchasing an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company's stock valued at $210,000 after purchasing an additional 19,601 shares in the last quarter. Institutional investors and hedge funds own 14.11% of the company's stock.
Analysts Set New Price Targets
ENTX has been the topic of several analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Entera Bio in a research note on Thursday, January 22nd. Wall Street Zen raised Entera Bio to a "sell" rating in a research note on Saturday, December 27th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Entera Bio in a research report on Monday, February 9th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $10.00.
Read Our Latest Stock Analysis on Entera Bio
About Entera Bio
(
Get Free Report)
Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.
The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
